Antibacterial agents

1. A compound according to Formula (II)

AA is an amino acid residue selected from the group consisting of L-Thr, L-allo-Thr, and L-Val, wherein AA is attached to -Z- at its N-terminus and to —NHOH at its C-terminus;

R is H—or CH 3 O—;

G is absent,

—CH═CH—, —C≡C—,

or —C≡C—C≡C—; and

Y is substituted or unsubstituted aryl or heteroaryl.

2. The compound of claim 1 , wherein AA is L-Thr.

3. The compound of claim 1 , wherein AA is L-allo-Thr.

4. The compound of claim 1 , wherein G is —C≡C—.

5. The compound of claim 1 , wherein G is —CH═CH—.

6. The compound of claim 1 , wherein Z is CH 2 and G is —C≡C—C≡C—.

7. The compound of claim 1 , wherein G is —C≡C—C≡C— or —CH═CH— and Y is a substituted or unsubstituted heteroaryl.

8. A compound according to Formula (III)

wherein:

R is H— or MeO—;

AA is an amino acid residue selected from the group consisting of L-Thr, L-allo-Thr, and L-Val, wherein AA is attached to —C(O)— at its N—terminus and to —NHOH at its C-terminus; and

R 1 and R 4 are independently H—, CH 3 —, CF 3 —, CH 3 CH 2 —, F—, HO—, MeO—, CF 3 O—, H 2 N—, Me 2 NCH 2 —, (AA) 1 —NH—, (AA) 1 -NHCH 2 —, R 3 NHCH 2 —, R 3′ NHCO—, R 3′ NHCOCH 2 —R 3′ NHCOCH 2 O—,

wherein (AA) 1 is an amino acid or dipeptide and is attached to —NH— or —NHCH 2 — at its C-terminus;

(AA) 2 is an amino acid or dipeptide and is attached to —C(O)— or —C(O)CH 2 — at its N-terminus;

R 3 is H—, lower alkyl, or aminoalkyl; and

R 3 is lower alkyl or aminoalkyl.

9. The compound of claim 8 , wherein AA is L-Thr.

10. The compound of claim 8 , wherein AA is L-allo-Thr.

11. The compound of claim 8 , wherein R 1 or R 4 is (AA) 1 —NH—.

12. The compound of claim 8 , wherein R 1 or R 4 is (AA) 1 —NHCH 2 —.

13. The compound of claim 8 , wherein R 1 or R 4 is

14. The compound of claim 8 , wherein R 1 or R 4 is

and AA is L-Thr or L-allo-Thr.

15. A compound according to Formula (IV)

wherein:

AA is L-Dap and is attached to —C(O)— at its N-terminus and to —NHOH at its C-terminus;

R=H—or F—; and

R 4 is selected from the group consisting of CH 3 CH 2 —, H 2 N—, Et 2 N—, HOCH 2 —, CF 3 —, CF 3 O—, H 2 N—CH 2 —CO—NH—, R 3 NHCOCH 2 — and R 3 NHCOCH 2 O—;

wherein R 3 is lower alkyl, hydroxyalkyl, aminoalkyl, or hydroxy.

16. A compound according to Formula (V)

wherein:

AA=L-Thr or L-Dap and is attached to —C(O)— at its N-terminus and to —NHOH at its C-terminus; and

R 4 is selected from the group consisting of HONHCO—CH(CHMeOH)—NH—CO—, HONHCO—CH(CH 2 NH 2 )—NH—CO—, (AA) 1 —CO—, (AA) 2 —NH—, HO—, HOCH 2 —, H 2 N—CH 2 —CONH—, R″NH—, R″NHCH 2 —,

wherein R″=Et-, hydroxyalkyl or H 2 N(CH 2 ) 2 —;

(AA) 1 is any amino acid and is attached to —CO— at its N-terminus;

(AA) 2 is alanine or β-alanine and is attached to —NH— at its C-terminus;

n is 0-1; and

m is 1-3.

17. The compound of claim 16 , wherein R 4 is

18. The compound of claim 16 , wherein R 4 is H 2 N—CH 2 —CONH—.

19. The compound of claim 16 , wherein R 4 is

20. The compound of claim 16 , wherein R 4 is HOCH 2 —.

21. A compound according to Formula (VI)

wherein:

AA=L-Thr or L-Dap and is attached to —C(O)— at its N-terminus and to —NHOH at its C-terminus;

R 4 =H—or CH 3 —; and

R 2 and R 3 are independently selected from the group consisting of H—, CH 3 —, H 2 N—, EtNH—, HO—, Cl—, CF 3 —,

H 2 NCH 2 CH 2 NHCH 2 —,

NH 2 —CH 2 —,

—RNH—CH 2 —,

wherein R=aminoalkyl and

(AA) 1 is any amino acid and is attached to —NH— or —NHCH 2 — at its C-terminus, and

with the proviso that R 2 and R 3 are not both H—.

22. The compound of claim 21 , wherein R 3 is HO—.

23. The compound of claim 21 , wherein R 3 is H 2 N—.

24. The compound of claim 21 , wherein R 3 is

25. The compound of claim 21 , wherein R 3 is AA 1 —NH—in the form of H 2 N—CH 2 —CONH—.

26. The compound of claim 21 , wherein R 3 is AA 1 —NH—CH 2 — in the form of H 2 N—CH 2 —CONHCH 2 —.

27. The compound of claim 21 , wherein R 3 is H 2 N—CH 2 CH 2 —NHCH 2 —.

28. The compound of claim 21 , wherein R 3 is NH 2 —CH 2 —.

29. A pharmaceutical composition comprising:

the compound according to claim 1 and a pharmaceutically acceptable excipient.

30. A pharmaceutical composition comprising:

the compound according to claim 8 and a pharmaceutically acceptable excipient.

31. A pharmaceutical composition comprising:

the compound according to claim 15 and a pharmaceutically acceptable excipient.

32. A pharmaceutical composition comprising:

the compound according to claim 16 and a pharmaceutically acceptable excipient.

33. A pharmaceutical composition comprising:

the compound according to claim 21 and a pharmaceutically acceptable excipient.

34. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 1 to the subject.

35. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 8 to the subject.

36. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 15 to the subject.

37. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 16 to the subject.

38. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 21 to the subject.

39. A compound according to Formula (VII)

wherein:

AA is L-Dap and is attached to —C(O)— at its N-terminus and to —NHOH at its C-terminus;

R is H—, or F—;

R 1 is H 2 N—, EtNH—, Et 2 N—, R 3 CONH—, NHCH 2 —, H 2 NCH 2 CONH—, or (AA) 1 —NH—;

wherein (AA) 1 is any amino acid and is attached to —NH— at its C-terminus, and

R 3 is a lower alkyl or aminoalkyl; and

R 4 is H—.

40. The compound according to claim 39 , wherein (AA) 1 is γAbu.

41. A pharmaceutical composition comprising:

the compound according to claim 39 and a pharmaceutically acceptable excipient.

42. A method of treating infection in a subject comprising:

administering an effective amount of the compound according to claim 39 to the subject.